Invention Grant
- Patent Title: Soluble heterodimeric CD94/NKG2 receptors fusion proteins
- Patent Title (中): 可溶性异二聚体CD94 / NKG2受体融合蛋白
-
Application No.: US12305678Application Date: 2007-06-22
-
Publication No.: US07932055B2Publication Date: 2011-04-26
- Inventor: Petrus Johannes Louis Spee , Søren Berg Padkær , Birgitte Nissen Friedrichsen , Inga Sig Nielsen Nørby
- Applicant: Petrus Johannes Louis Spee , Søren Berg Padkær , Birgitte Nissen Friedrichsen , Inga Sig Nielsen Nørby
- Applicant Address: DK Bagsvaerd
- Assignee: Novo Nordisk A/S
- Current Assignee: Novo Nordisk A/S
- Current Assignee Address: DK Bagsvaerd
- Agent Teresa Chen
- Priority: EP06115901 20060622
- International Application: PCT/EP2007/056276 WO 20070622
- International Announcement: WO2007/147898 WO 20071227
- Main IPC: C07K14/725
- IPC: C07K14/725 ; C12P21/00

Abstract:
Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.
Public/Granted literature
- US20090281035A1 Soluble Heterodimeric Receptors and Uses Thereof Public/Granted day:2009-11-12
Information query